I am scheduled for SBRT at UCLA for 1/12/ 2023. However , UCSF did a path review of MSK's Biopsy report, and indicated that UCSF found additionally :
1. the presence of "expansile cribriform subtype"
2. the "possible identification of extracapsular extension" described below:
"Tumor is in loose fibrous tissue immediately next to adipose tissue, that while NOT DEFINITE ,is HIGHLY SUSPICIOUS for EXTRAPROSTATIC EXTENSION".
MSK had neither of those findings in their original report.
The Chief RO of UCSD said that she is concerned that the SBRT might miss this ECE which may result in a recurrence for which they couldn't retreat and I would be stuck on Hormone therapy for life.
She highly suggested IMRT and 4 months of ADT. (I can't have adt due to cardiac conditions)
She wanted me to personally confirm with the MSK Pathologist that there was no ECE. Please give me your thoughts.
.(The ECE was just a possibility from path report not from an MRI.)
1.Is the RO right about you have one chance to treat the prostate bed w SBRT, IMRT, BRACHY and if you miss the ECE you can't retreat the recurrence from the miss? and then Hormones?
2 Is IMRT maybe the better treatment because its longer and covers more territory of the prostate bed.
3. Will the pathologists talk to you directly? has anyone talked to a pathologist that reviewed or did their biopsy?
4. The ECE is not even clearly indicated , it is NOT DEFINITE & HIGHLY SUSPICIOUS FOR EXTRACAPSULAR EXTENSION should it be an important consideration?
5. Sloan Kettering says their pathologist says NO CRIBIFORM and they say Pathology is Subjective , difference of opinions?????
6. Should I get a third Review from Dr. Epstein at Hopkins, or will that confuse things more..
Sorry , for the long post but their continually changing the playing field with choices that may injure you QOL forever..and you really don't know who to believe ,there all centers of excellence.
ALL RESPONSES & THOUGHTS APPRECIATED AND WELCOMED!
TALL ALLEN WOULD APPRECIATE YOUR SAGE COMMENTS!
Gleason 7...4-3..62...